Holen Sie sich die Stockscreener-App
49.39
0.77%
-0.4654
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$49.86
Offen:
$50.33
24-Stunden-Volumen:
211.68K
Relative Volume:
0.19
Marktkapitalisierung:
$5.87B
Einnahmen:
$3.13M
Nettoeinkommen (Verlust:
$-545.28M
KGV:
-8.9483
EPS:
-5.52
Netto-Cashflow:
$-401.27M
1W Leistung:
-9.55%
1M Leistung:
-8.06%
6M Leistung:
-17.73%
1J Leistung:
+55.88%
1-Tages-Spanne:
$49.26
$50.45
1-Wochen-Bereich:
$49.26
$55.14
52-Wochen-Spanne:
$30.68
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CYTK | 49.41 | 5.87B | 3.13M | -545.28M | -401.27M | -5.52 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.93 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - Yahoo Finance
Cytokinetics and Bayer ink deal for aficamten in Japan - The Pharma Letter
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Bayer acquires rights to Cytokinetics' heart drug in Japan - MSN
Royce & Associates LP Has $1.28 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics CEO Robert Blum sells shares for $252,750 - Investing.com
Cytokinetics CEO Robert Blum sells shares for $252,750 By Investing.com - Investing.com UK
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HC - GuruFocus.com
Cytokinetics, Bayer in Japan Licensing Pact for Aficamten - MarketWatch
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer - Yahoo Finance
First Turn Management LLC Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan - Yahoo Finance UK
Bayer: exclusive licensing agreement with Cytokinetics in Japan - Marketscreener.com
Bayer secures rights to heart drug in multi-million deal - Marketscreener.com
Cytokinetics Lands €50M Bayer Deal for HCM Drug Aficamten in Japan, €580M+ Potential | CYTK Stock News - StockTitan
H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - The Manila Times
Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com
Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com
Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells $370,880 in stock - Investing.com
Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat
FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com
Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan
Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference - Yahoo Finance
Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Yahoo Finance
HC Wainwright Forecasts Reduced Earnings for Cytokinetics - MarketBeat
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com
Van ECK Associates Corp Has $3.80 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics started at outperform by RBC, valuation cited - MSN
Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign - MM+M Online
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Cytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript - Insider Monkey
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Cytokinetics: Q3 Earnings Snapshot - AOL
Cytokinetics director resigns, board reduced to eight By Investing.com - Investing.com UK
Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strate - GuruFocus.com
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Cytokinetics Inc earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Cytokinetics Reports Third Quarter 2024 Financial Results - The Manila Times
International Assets Investment Management LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):